Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis

Read more at globenewswire.com